Drugs / PAC-1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03332355 | Oct 2017 → Dec 2021 | anaplastic astrocytoma, glioblastoma | Vanquish Oncology, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02355535 | Feb 2015 → May 2020 | cancer, pancreatic neuroendocrine tumor | Vanquish Oncology, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04589832 | Jan 2021 → Mar 2022 | uveal melanoma | Arkadiusz Z. Dudek, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT03927248 | Sep 2020 → Sep 2021 | renal cell carcinoma | HealthPartners Institute | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAC-1 | “Pilot Study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for” NCT03927248 ↗ |
| Known as | procaspase-activating compound 1 | “(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2” NCT03332355 ↗2“Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.” NCT02355535 ↗ “Pilot Study of Nivolumab and Procaspase Activating Compound-1 (PAC-1) for” NCT03927248 ↗ |
| Action | Activate | “procaspase-activating compound 1 (PAC-1) directly activates PC-3” PMID 36470974 ↗ Dec 2022 |
| Modality | Small molecule | “PAC-1), a small molecule that activates procaspase -3 to caspase-3” NCT02355535 ↗ |
| Route | Oral | “PAC-1 is taken orally on days 1-21 of a 28-day cycle.” NCT02355535 ↗ |